NCT03465436 - A Study of Lasmiditan on the Heart in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2011

Primary Completion Date

December 20, 2011

Study Completion Date

December 20, 2011

Conditions

Healthy

Interventions

DRUG

Lasmiditan

100 mg administered orally (PO)

DRUG

Lasmiditan

400 mg administered PO

DRUG

Placebo

Placebo administered for lasmiditan or moxifloxacin

DRUG

Moxifloxacin

400 mg moxifloxacin administered PO

Trial Locations (1)

14050

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Berlin